Amarantus Buys Power3's IP Portfolio for $40K
December 26, 2012
Amarantus Buys Power3's IP Portfolio for $40K
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Power3 Inks Parkinson's Protein Biomarker Deal with Amarantus, Looks to Enter CRO Space
January 30, 2012 / ProteoMonitor - BU Team IDs RNA-Binding Proteins as Potential Alzheimer's Biomarkers
June 22, 2012 / ProteoMonitor - Durin Tech Expands Antibody-Array Dx Efforts to Parkinson's, Shows High Accuracy
March 9, 2012 / ProteoMonitor - Protein Biomarkers for Alzheimer's Predicted to Represent Cumulative $9B Market Over Next Decade
June 3, 2011 / ProteoMonitor - Australian Team Developing Plasma Protein Panel for Predicting Amyloid Burden in Alzheimer's Patients
May 3, 2013 / ProteoMonitor